SCHEMBL4835334

SCHEMBL4835334

COC(=O)c1ccc(O)cc1NC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C19 P33261 1/20 0.58
KDM4E B2RXH2 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
MAPT P10636 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 2/20 0.57
HSD17B10 Q99714 2/20 0.56
MAPK1 P28482 1/20 0.56
DHODH Q02127 1/20 0.56
TP53 P04637 1/20 0.56
ELANE P08246 1/20 0.54
PRTN3 P24158 1/20 0.54
POLB P06746 1/20 0.54
GAA P10253 1/20 0.54
DEGS1 O15121 1/20 0.54
PDCD1 Q15116 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14428246 0.94 HDAC1 (0.57) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL2275077 0.92 KDM4E (0.66) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL2271167 0.88 KDM4E (0.64) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL14075405 0.85 TSHR (0.70) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL1318436 0.85 MEN1 (0.56) TSHRKDM4EMEN1KMT2AMAPT
SCHEMBL2274003 0.85 HDAC2 (0.66) TSHRKDM4EMEN1KMT2AMAPT
SCHEMBL12369429 0.84 KDM4E (0.60) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL12369435 0.83 HDAC2 (0.67) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL4829005 0.83 KDM4E (0.63) TSHRCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL4800345 0.83 KDM4E (0.59) TSHRCYP1A2CYP2D6CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
CN-1882324-A Substituted aryloximes WYETH CORP (US) 2006-12-20 CN disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 TSHR 1688/4885CYP1A2 15/4885CYP2D6 22/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 TSHR 580/4885CYP1A2 22/4885CYP2D6 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.